BSD Medical Corporation’s President & CEO Interviewed by The Wall Street Transcript

  BSD Medical Corporation’s President & CEO Interviewed by The Wall Street

                Full Interview PDF Available on BSD’s web site

Business Wire

SALT LAKE CITY -- August 19, 2013

BSD Medical (NASDAQ:BSDM) today announced that President and Chief Executive
Officer Harold Wolcott was recently interviewed by The Wall Street Transcript
(TWST). Mr. Wolcott’s interview appeared in the publication’s August 5, 2013,
Medical Devices Report. The full interview is available on BSD Medical’s web
site at The full
Medical Devices Report can be acquired through contacting The Wall Street
Transcript (212-952-7400 or

In the interview, Mr. Wolcott discusses BSD Medical’s pioneering medical
device systems that utilize heat therapy for the treatment of cancer. BSD
Medical’s two approaches, microwave ablation and hyperthermia, have made the
treatment of cancer less invasive and more cost effective. The MicroThermX^®
Microwave Ablation System (MicroThermX) delivers stand-alone ablation therapy
that utilizes microwave energy to treat diseased cancerous tissue. A
MicroThermX treatment usually takes 10 to 15 minutes and may allow the patient
to return home the same day. Hyperthermia therapy is used to increase the
effectiveness of radiation and/or chemotherapy for the treatment of certain

In addition to BSD Medical’s technology, Mr. Wolcott spoke about BSD’s recent
distribution agreement for the MicroThermX with Terumo Europe NV. He noted
that the agreement with Terumo is a historic milestone for the company and
further validates the many medical advantages of the company’s innovative
microwave ablation technology.

Mr. Wolcott said of the recent interview with TWST, “It is an exciting time at
BSD Medical and we are thrilled to share our story with the readers of The
Wall Street Transcript as well as with the larger professional investment

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia), while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at

About the Wall Street Transcript

The Wall Street Transcript (“TWST”) is a financial interview transcripts
publication and Web site that has been in business for over 40 years. TWST
interviews public company CEOs, equity analysts and money managers in a wide
variety of industries, and publishes the transcripts of these interviews on
the Web at and in a bi-weekly print edition.

Statements contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date.


BSD Medical Corporation
William (Bill) S. Barth, 801-972-5555
Financial Profiles
Tricia Ross, 916-939-7285
Press spacebar to pause and continue. Press esc to stop.